Tuberculosis drug resistance: A global threat

Clinical Infectious Diseases

Volumn 36, Issue SUPPL. 1, 2003, Pages

  Nachega, Jean B ^a   Chaisson, Richard E ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOSALICYLIC ACID; CAPREOMYCIN; CYCLOSERINE; ETHAMBUTOL; ETHIONAMIDE; GATIFLOXACIN; ISONIAZID; KANAMYCIN; LEVOFLOXACIN; MOXIFLOXACIN; OFLOXACIN; PYRAZINAMIDE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; STREPTOMYCIN; TUBERCULOSTATIC AGENT;

AFRICA; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; ASIA; BACTERIUM ISOLATION; CHEMOTHERAPY; CONVULSION; EARLY DIAGNOSIS; EPIDEMIC; EUROPE; GASTROINTESTINAL DISEASE; GEOGRAPHY; HISTORY OF MEDICINE; HUMAN; HYPERSENSITIVITY; LIVER TOXICITY; MULTIDRUG RESISTANCE; NEPHROTOXICITY; OTOTOXICITY; PREVALENCE; PRIORITY JOURNAL; PSYCHOSIS; RASH; TUBERCULOSIS; VESTIBULAR DISORDER; WESTERN HEMISPHERE;

ANTITUBERCULAR AGENTS; DRUG RESISTANCE, BACTERIAL; DRUG RESISTANCE, MULTIPLE; HUMANS; TUBERCULOSIS; WORLD HEALTH;

EID: 0037439496     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/344657     Document Type: Article

References (52)

1. Raviglione MC, Snider DE, Kochi A. Global epidemiology of tuberculosis morbidity and mortality of a world wide epidemic. JAMA 1995; 273:220-6.
2. Dye C, Scheele S, Dolin P, et al. Global burden of tuberculosis: estimated incidence, prevalence, and mortality by country. JAMA 1999; 285:677-86.
3. World Health Organization. World health report 1999: making a difference. Geneva: World Health Organization, 1999.
4. Raviglione MC, Harries AD, Msiska R, et al. Tuberculosis and HIV: current status in Africa. AIDS 1997; 11(Suppl B):S115-23.
5. Pyle MM. Relative numbers of resistant tubercle bacilli in sputum of patients before and during treatment of streptomycin. Proc Staff Meetings Mayo Clinic 1947; 22:465.
6. Medical Research Council. Streptomycin treatment of pulmonary tuberculosis. Br Med J 1948; 2:769-82.
7. Medical Research Council. Treatment of pulmonary tuberculosis with para-aminosalicylic acid and streptomycin. Br Med J 1949; 2:1521-5.
8. Frieden TR, Sterling T, Pablos-Mendez A, Kilburn JO, Cauthen GM, Dooley SW. The emergence of drug resistance tuberculosis in New York City. N Engl J Med 1993; 328:521-6.
9. Edlin BR, Tokars JI, Grieco MH, et al. An outbreak of tuberculosis caused by multiple-drug resistant tuberculosis among hospitalized patients with the acquired immunodeficiency syndrome. N Engl J Med 1992; 326:1514-21.
10. Fischl MA, Uttamchandani RB, Daikos GL, et al. An outbreak of tuberculosis caused by multiple-drug resistant tubercle bacilli among patients with HIV infection. Ann Intern Med 1992; 117:177-83.
11. Coninx R, Mathieu C, Debacker M, et al. First line tuberculosis therapy and drug-resistant Mycobacterium tuberculosis in prisons. Lancet 1999; 353:969-73.
12. Espinal MA, Kim SJ, Suarez PG, et al. Standard short-course chemotherapy for drug resistant tuberculosis: treatment outcome in six countries. JAMA 2000; 283:2537-45.
13. Garcia-Garcia M, Ponce-de-Leon A, Jimenez-Corona ME, et al. Clinical consequences and transmissibility of drug resistant tuberculosis in Southern Mexico. Arch Intern Med 2000; 160:630-6.
14. Goble M, Iseman MD, Madsen LA, White D, Ackerson L, Horsburgh CR. Treatment of 171 patients with pulmonary tuberculosis resistant to isoniazid and rifampin. N Engl J Med 1993; 328:527-32.
15. Park MM, Davis AL, Schluger NW, Cohen H, Rom WN. Outcome of MDR-TB patients, 1983-1993: prolonged survival with appropriate therapy. Am J Respir Crit Care Med 1996; 153:317-24.
16. Frieden TR, Fujiwara PI, Washko RM, Hamburg MA. Tuberculosis in New York City: turning the tide. N Engl J Med 1995; 333:229-33.
17. Schluger NW. The impact of drug resistance on the global tuberculosis epidemic. Int J Tuberc Lung Dis 2000; 4:S71-5.
18. World Health Organization. Anti-tuberculosis drug resistance in the world: the WHO/IUATLD global project on antituberculous drug resistance surveillance 1994-97. WHO/TB/97,229. Geneva: World Health Organization, 1997.
19. WHO/IUATLD Global Project on Anti-Tuberculous Drug Resistance Surveillance: antituberculous drug resistance in the world. Report 2: Prevalence and trends. Geneva: World Health Organization, 2000.
20. Espinal MA, Laszlo A, Simonsen L, et al. Global trends in resistance to antituberculosis drugs. N Engl J Med 2001; 344:1294-303.
21. Willcox PA. Drug resistant tuberculosis: worldwide trends, problems specific to Eastern Europe and other hotspots, and the threat to developing countries. Curr Opinion Pulm Med 2001; 7:148-53.
22. Holden C. Stalking a killer in Russia's prisons. Science 1999; 286:1670.
23. Portaels F, Rigouts L, Bastian I. Addressing multidrug resistant tuberculosis in penitentiary hospitals and in the general population of the former Soviet Union. Int J Tuberc Lung Dis 1999; 3:582-8.
24. Kimerling ME, Kluge H, Vezhnina N, et al. Inadequacy of the current WHO re-treatment regimen in a central Siberian prison: treatment failure and MDR-TB. Int J Tuberc Lung Dis 1999; 3:451-3.
25. Kenyon TA, Mwasekaga MJ, Huebner R, et al. Low levels of drug resistance amidst rapidly increasing tuberculosis and human immunodeficiency virus co-epidemics in Botswana. Int J Tuberc Lung Dis 1999; 3:4-11.
26. Centers for Diseases Control. Nosocomial transmission of multidrug resistant tuberculosis among HIV-infected persons - Florida and New York 1988-91. MMWR Morb Mortal Wkly Rep 1991; 40:585-91.
27. David HL. Probability distribution of drug resistant mutants in unselected populations of Mycobacterium tuberculosis. Appl Microbiol 1970; 20:810-4.
28. Heifets LB, Cangelosi GA. Drug susceptibility testing of Mycobacterium tuberculosis: a neglected problem at the turn of the century. Int J Tuberc Lung Dis 1999; 3:564-81.
29. Zhang Y, Heym B, Allen B, et al. The catalase-peroxidase gene and isoniazid resistance in tuberculosis. Nature 1992; 358:591.
30. Banerjee A, Dubnau E, Ouernard A, et al. inhA, a gene encoding a target for isoniazid and ethionamide in Mycobacterium tuberculosis. Science 1994; 263:227-30.
31. Mduli K, Slaydon RA, Zhu Y, et al. Inhibition of a Mycobacterium tuberculosis beta-ketoacyl ACP synthase by isoniazid. Science 1998; 280:1607-10.
32. Wilson TM, Collins DM. ahpC, a gene involved in isoniazid resistance of the Mycobacterium tuberculosis complex. Mol Microbiol 1996; 19:1025-34.
33. Telenti A, Imboden P, Marchesi F, et al. Detection of rifampicin resistant mutations in Mycobacterium tuberculosis. Lancet 1993; 341:647-50.
34. Mitchison DA. The action of antituberculosis drugs in short-course chemotherapy. Tubercle 1985; 66:219-25.
35. American Thoracic Society. Diagnostic standards and classification for tuberculosis. Am J Respir Crit Care Med 2000; 161:1376-95.
36. Caviedes L, Lee T-S, Gilman RH, et al. Rapid, efficient detection and drug susceptibility testing of Mycobacterium tuberculosis in sputum by microscopic observation of broth cultures. J Clin Microbiol 2000; 38:1203-8.
37. Yajko DM, Madej JJ, Lancaster MV, et al. Colorimetric method for determining MICs of antimicrobial agents for Mycobacterium tuberculosis. J Clin Microbiol 1995; 33:2324-7.
38. El-Hajj HH, Marras SA, Tyagi S, et al. Detection of rifampin resistance in Mycobacteriurn tuberculosis in a single tube with molecular beacons. J Clin Microbiol 2001; 39:4131-7.
39. Grosset J. Systematic drug susceptibility testing: a necessary component of the "DOTS Plus" strategy? Int J Tuberc Lung Dis 1999; 3:549-50.
40. Mitchson DA, Nunn AJ. Influence of initial drug resistance on the response to short-course chemotherapy of tuberculosis. Am Rev Respir Dis 1986; 133:423-30.
41. American Thoracic Society/CDC. Treatment of tuberculosis and tuberculosis infection in adults and children. Am J Respir Crit Care Med 1994; 149:1359-74.
42. Iseman MD. Treatment of multidrug-resistant tuberculosis. N Engl J Med 1993; 329:784-91.
43. Kritski AL, de Jesus LSR, Andrade MK, et al. Re-treatment tuberculosis cases: factors associated with drug resistance and adverse outcomes. Chest 1997; 111:1162-7.
44. Hong Kong Chest Service/British Medical Research Council. Controlled trial of 6-month and 9-month regimens of daily and intermittent streptomycin plus isoniazid plus pyrazinamide for pulmonary tuberculosis in Hong Kong. Am Rev Respir Dis 1977; 115:727-35.
45. Turret GS, Telzak EE, Torian LV, et al. Improved outcomes for patients with multidrug-resistant tuberculosis. Clin Infect Dis 1995; 21:1238-44.
46. Tahaoglu K, Torun T, Sevim T, et al. The treatment of multidrug-resistant tuberculosis in Turkey. N Engl J Med 2001; 345:170-4.
47. Iseman MD. Treatment of multidrug resistant tuberculosis well-resourced countries [abstract]. The 32nd IUATLD World Conference on Lung Health (Paris), 1-4 November 2001.
48. Pomerantz BJ, Cleveland JC Jr, Oslon HK, Pomerantz M. Pulmonary resection for multi-drug resistant tuberculosis. J Thorac Cardiovasc Surg 2001; 121:448-53.
49. Farmer P. The major infectious diseases in the world - to treat or not to treat? N Engl J Med 2001;345:208-10.
50. Farmer PE, Furin JJ, Shin SS, et al. The clinical management of multidrug-resistant tuberculosis. J Respir Dis 2000; 21:53-6.
51. Farmer PE, Bayona J, Shin S, et al. Preliminary results of community-based MDR-TB treatment in Lima, Peru. Int J Tuberc Lung Dis 1998; 2(Suppl):S371.
52. Kim JY, Furin JJ, Shakow AD, et al. Treatment of multidrug-resistant tuberculosis (MDR-TB): new strategies for procuring second- and third-line drugs. Int J Tuberc Lung Dis 1999; 3(Suppl 1):S81.